Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Posts Tagged ‘susan g. komen’

Susan G. Komen® Launches New Podcast for Those Touched by Breast Cancer

Posted by fidest press agency su venerdì, 24 maggio 2019

Susan G. Komen®, the world’s leading breast cancer organization, announced the launch of a new podcast, Real PinkTM, debuting on Apple Podcasts, Google Play, Spotify, Stitcher and all other podcast platforms this month. The Real Pink podcast is a weekly series that brings people together for meaningful and honest conversations about breast cancer – tackling tough, emotional or life-changing issues and topics.Each week, host Adam Walker will interview people who have been impacted by breast cancer, or those on the front lines in the fight against the disease, including celebrities, survivors, people living with the disease, physicians, researchers and advocates to offer their personal perspectives and first-hand information and guidance. Through Real Pink, Susan G. Komen will strive to help those affected by breast cancer – including patients and the people in their lives who love them – by providing the information needed to make informed decisions.In Real Pink’s debut episode, Walker and Samantha Harris, entertainment journalist, Emmy-winning television host and breast cancer survivor, discuss her emotional journey of diagnosis and treatment. Real Pink is available now on Apple Podcasts, Google Play, Spotify, Stitcher and iHeart Radio. New episodes will be available every Monday and will include interviews from guests such as Titus O’Neil, WWE Superstar and Kikkan Randall, 5-time Olympic cross-country skiing champion and breast cancer survivor. To learn more about Susan G. Komen’s new podcast series, visit https://realpink.komen.org/.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Susan G. Komen Statement on TAILORx Study Citing Chemotherapy Not Needed for Some Breast Cancer Patients

Posted by fidest press agency su martedì, 5 giugno 2018

Susan G. Komen®, the world’s leading breast cancer organization, issued the following statement regarding a new study partially funded by the organization – called Trial Assigning Individualized Options for Treatment, or TAILORx. The study shows that many women with early stage breast cancer may not need to undergo chemotherapy treatment. The study was published today in the New England Journal of Medicine and presented this weekend at a meeting of the American Society of Clinical Oncology.
The study found that 70 percent of women with early stage breast cancers that are HER2 negative and are sensitive to estrogen, may be able to forgo chemotherapy and its toxic side effects. By using individuals’ Oncotype DX Genomic testing score, researchers found some patients need take only hormone therapy, drugs that block the hormone estrogen or stops the body from making it. This statement can be attributed to Victoria Wolodzko, Komen’s Senior Vice President of Mission.
“Susan G. Komen has been concerned for years about the toxic side effects of chemotherapy, because while it can save lives, it also can potentially cause heart and nerve damage, and also leave patients vulnerable to infection and increase the risk of leukemia later in life. This is why we have funded a body of research that seeks to more precisely treat breast cancers and potentially avoid chemotherapy. This study, which was supported in part by Komen funding, suggests that we have the potential to use Genomic testing to tell some women more precisely whether they would benefit from chemotherapy or not.”According to the researchers, the study definitively identifies the 70% of women with early-stage, hormone-receptor positive, HER-2 negative, node-negative breast cancer who do not benefit from chemotherapy and the 30% of those women for whom chemotherapy can be lifesaving. For all women who fall in the mid-range of Oncotype Dx test scores regardless of age, there was a clear and large chemotherapy benefit. In women younger than 50, those with lower scores showed modest (2%) chemotherapy benefit, which gradually grew as scores increased. This important finding reveals how Oncotype DX testing can lead to a new level of precision treatment.The TAILORx trial was independently designed and conducted by ECOG-ACRIN under the sponsorship of the National Cancer Institute (NCI), and was the largest adjuvant breast cancer treatment trial ever conducted. It enrolled 10,273 women with early-stage breast cancer across approximately 1,200 sites in the United States and 5 additional countries. Komen funded Dr. Joseph A. Sparano of Montefiore Medical Center in New York, the leader of the study, to create a biospecimen bank focused on defining tumor and host factors contributing to recurrence of breast cancer occurring more than five years after diagnosis.Komen has invested more than $266 million in over 590 research grants and nearly 100 clinical trials focused on precision medicine.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »